Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug

By: via Benzinga
Context Therapeutics Inc. (NASDAQ: CNTX) and Integral Molecular are teaming up to develop an anti-claudin 6 (CLDN6) bispecific ...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.